Bell Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bell Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71K	Hold	68	–	–	﹤0.01%	1106
2026 Q1	$3.23K	Hold	68	–	–	﹤0.01%	1134
2025 Q4	$3.57K	Hold	68	–	–	﹤0.01%	1123
2025 Q3	$4.41K	Hold	68	–	–	﹤0.01%	992
2025 Q2	$3.31K	Buy	+68	New	+$2.63K	﹤0.01%	1156
2025 Q1	–	Sell	-40	Closed	-$1.57K	–	1914
2024 Q4	$1.57K	Buy	40 +13	+48%	+$614	﹤0.01%	1422
2024 Q3	$1.27K	Buy	27 +11	+69%	+$558	﹤0.01%	1522
2024 Q2	$865	Sell	16 -5	-24%	-$289	﹤0.01%	1649
2024 Q1	$1.43K	Buy	21 +8	+62%	+$573	﹤0.01%	1482
2023 Q4	$814	Sell	13 -21	-62%	-$1.16K	﹤0.01%	1643
2023 Q3	$1.54K	Buy	+34	New	+$1.76K	﹤0.01%	1395
2023 Q1	–	Sell	-9	Closed	-$366	–	1932
2022 Q4	$366	Buy	+9	New	+$477	﹤0.01%	1910
2022 Q3	–	Sell	-9	Closed	-$1K	–	1763
2022 Q2	$1K	Buy	+9	New	+$529	﹤0.01%	1383
2021 Q4	$1K	Sell	9 -4	-31%	-$349	﹤0.01%	1393
2021 Q3	$1K	Buy	+13	New	+$1.63K	﹤0.01%	1326

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bell Investment Advisors's CRSP Position: Q2 2026 in Review

Bell Investment Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 68 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Bell Investment Advisors first reported a position in CRSP in Q3 2021 and has held it in 15 quarters since. The position peaked at $4.41K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Bell Investment Advisors held 68 shares of CRISPR Therapeutics worth $3.71K as of Q2 2026.
Bell Investment Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1106 holding.
Bell Investment Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 15 quarters since.
Bell Investment Advisors's CRISPR Therapeutics position peaked at $4.41K in Q3 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.